BR0112690A - Cilansetron-containing drug for the treatment of non-constipative male ibs patients - Google Patents

Cilansetron-containing drug for the treatment of non-constipative male ibs patients

Info

Publication number
BR0112690A
BR0112690A BR0112690-3A BR0112690A BR0112690A BR 0112690 A BR0112690 A BR 0112690A BR 0112690 A BR0112690 A BR 0112690A BR 0112690 A BR0112690 A BR 0112690A
Authority
BR
Brazil
Prior art keywords
treatment
cilansetron
constipative
ibs patients
containing drug
Prior art date
Application number
BR0112690-3A
Other languages
Portuguese (pt)
Inventor
Werner Cautreels
Claus Rudolf Steinborn
Heinz Guenter Krause
Steven David Caras
Egbertus Hendrikus Biesheuvel
Albertus Hermannus Plekkenpol
Original Assignee
Solvay Pharm Gmbh
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Priority claimed from DE10123447A external-priority patent/DE10123447A1/en
Application filed by Solvay Pharm Gmbh filed Critical Solvay Pharm Gmbh
Publication of BR0112690A publication Critical patent/BR0112690A/en

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/4985—Pyrazines or piperazines ortho- or peri-condensed with heterocyclic ring systems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/4164—1,3-Diazoles
    • A61K31/4178—1,3-Diazoles not condensed 1,3-diazoles and containing further heterocyclic rings, e.g. pilocarpine, nitrofurantoin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/4164—1,3-Diazoles
    • A61K31/4184—1,3-Diazoles condensed with carbocyclic rings, e.g. benzimidazoles
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/4353—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems
    • A61K31/437—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems the heterocyclic ring system containing a five-membered ring having nitrogen as a ring hetero atom, e.g. indolizine, beta-carboline
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/439—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom the ring forming part of a bridged ring system, e.g. quinuclidine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/496—Non-condensed piperazines containing further heterocyclic rings, e.g. rifampin, thiothixene or sparfloxacin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/535—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one oxygen as the ring hetero atoms, e.g. 1,2-oxazines
    • A61K31/5375—1,4-Oxazines, e.g. morpholine
    • A61K31/538—1,4-Oxazines, e.g. morpholine ortho- or peri-condensed with carbocyclic ring systems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/06—Anti-spasmodics, e.g. drugs for colics, esophagic dyskinesia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Epidemiology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)

Abstract

"MEDICAMENTO CONTENDO CILANSETRON PARA O TRATAMENTO DE PACIENTES IBS MASCULINOS NãO-OBSTIPATIVOS". A presente invenção refere-se à utilização de Cilansetron para o tratamento de pacientes IBS masculinos não obstipativos."MEDICINAL PRODUCT CONTAINING CILANSETRON FOR THE TREATMENT OF NON-OBSTIPATIVE MALE IBS PATIENTS". The present invention relates to the use of Cilansetron for the treatment of non-constipative male IBS patients.

BR0112690-3A 2000-07-26 2001-07-18 Cilansetron-containing drug for the treatment of non-constipative male ibs patients BR0112690A (en)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
DE10036645 2000-07-26
DE10123447A DE10123447A1 (en) 2000-07-26 2001-05-14 Cilansetron-containing medicines for the treatment of non-obstipative male IBS patients
PCT/EP2001/008260 WO2002007713A2 (en) 2000-07-26 2001-07-18 Medicaments containing cilansetron for treating non-obstipated male ibs patients

Publications (1)

Publication Number Publication Date
BR0112690A true BR0112690A (en) 2003-06-24

Family

ID=26006529

Family Applications (1)

Application Number Title Priority Date Filing Date
BR0112690-3A BR0112690A (en) 2000-07-26 2001-07-18 Cilansetron-containing drug for the treatment of non-constipative male ibs patients

Country Status (16)

Country Link
EP (1) EP1307195A2 (en)
JP (1) JP2004504343A (en)
CN (1) CN1444479A (en)
AR (1) AR028970A1 (en)
AU (1) AU2001276409A1 (en)
BR (1) BR0112690A (en)
CA (1) CA2417677A1 (en)
CZ (1) CZ2003158A3 (en)
HU (1) HUP0301479A2 (en)
IL (1) IL153972A0 (en)
MX (1) MXPA02012917A (en)
NO (1) NO20030373D0 (en)
PL (1) PL363517A1 (en)
RU (1) RU2003104798A (en)
SK (1) SK1272003A3 (en)
WO (1) WO2002007713A2 (en)

Families Citing this family (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB0216027D0 (en) 2002-07-10 2002-08-21 Arachnova Therapeutics Ltd New therapeutic use
WO2005073220A1 (en) * 2004-01-30 2005-08-11 Yamanouchi Pharmaceutical Co., Ltd. Remedy for irritable bowel syndrome with diarrhea
NZ541656A (en) * 2004-01-30 2008-05-30 Astellas Pharma Inc The use of ramosetron hydrochloride for diarrhea-predominant irritable bowel syndrome
JP4632204B2 (en) * 2005-09-21 2011-02-16 アステラス製薬株式会社 Antidiarrheal irritable bowel syndrome treatment
US7662831B2 (en) 2006-07-27 2010-02-16 Wyeth Llc Tetracyclic indoles as potassium channel modulators
US7601856B2 (en) 2006-07-27 2009-10-13 Wyeth Benzofurans as potassium ion channel modulators

Family Cites Families (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB9721139D0 (en) * 1997-10-07 1997-12-03 Glaxo Group Ltd Medicaments
GB9930077D0 (en) * 1999-12-20 2000-02-09 Glaxo Group Ltd Medicaments

Also Published As

Publication number Publication date
SK1272003A3 (en) 2003-07-01
RU2003104798A (en) 2004-06-27
NO20030373L (en) 2003-01-24
AR028970A1 (en) 2003-05-28
CN1444479A (en) 2003-09-24
CZ2003158A3 (en) 2003-08-13
PL363517A1 (en) 2004-11-29
NO20030373D0 (en) 2003-01-24
CA2417677A1 (en) 2003-01-27
JP2004504343A (en) 2004-02-12
MXPA02012917A (en) 2003-05-14
WO2002007713A2 (en) 2002-01-31
EP1307195A2 (en) 2003-05-07
IL153972A0 (en) 2003-07-31
HUP0301479A2 (en) 2003-09-29
AU2001276409A1 (en) 2002-02-05
WO2002007713A3 (en) 2002-11-14

Similar Documents

Publication Publication Date Title
AR020662A1 (en) POLYCYCLIC DIHYDROTIAZOL COMPOUNDS, PROCEDURES FOR THE PREPARATION, MEDICATION, PROCEDURE FOR THE PREPARATION OF SUCH MEDICINAL PRODUCT AND THE USE OF SUCH COMPOUNDS FOR THE PREPARATION OF A MEDICINAL PRODUCT.
BR0112591A (en) Acridine derivatives and their application as a medicine
BR0112044A (en) Eradication therapy medicinal product packaging
NO20031018D0 (en) Controlled release oxymorphone preparations
BR0112589A (en) Heteroaryl derivatives and their application as a medicine
NO324227B1 (en) Cyclopropyl-fused pyrrolidine-based compounds, pharmaceutical compositions and combinations containing them as well as the use thereof for the manufacture of medicaments for the treatment of diseases
IL149147A0 (en) Use of oxcarbazepine for the manufacture of oral dosage form medicament
MX9207495A (en) TETRAHYDROISOQUINOLINE COMPOUNDS, PROCEDURE FOR THE PREPARATION AND PHARMACEUTICAL COMPOSITIONS CONTAINING THEM.
DE50311898D1 (en) FREDERICAMYCIN DERIVATIVES AS A MEDICAMENT FOR TUMOR TREATMENT
DE60034240D1 (en) DRUGS FOR THE TREATMENT OF MALIGNER TUMORS
BR0114344A (en) Retinoids for Emphysema Treatment
DK1383752T3 (en) Deuterated 3-piperidinopropiophenones as well as drugs containing these compounds
TR200101633T2 (en) Pharmaceutical composition
AR035889A1 (en) CITRATE OF 5,7,14-TRIAZATETRACICLO [10.3.1.02,11.04,9] HEXADECA-2 (11), 3,5,7,9- PENTAENE AND PHARMACEUTICAL COMPOSITIONS CONTAINING IT AND ITS USE FOR THE DEVELOPMENT OF MEDICINES
BR0112807A (en) Indole derivatives and their application as a medicine
ATE360428T1 (en) ANALGESIC MEDICINAL PRODUCT
BR0112690A (en) Cilansetron-containing drug for the treatment of non-constipative male ibs patients
EE200200088A (en) Use of bis-sulfonamides in the manufacture of a medicament for the prevention or treatment of hyperlipidemia
BR0211223A (en) Substituted 4-aminocyclohexanol derivatives
HUP0200145A2 (en) Use of tianeptin in the production of medicaments to treat neurodegenerative pathologies
SE0004827D0 (en) Therapeutic compounds
CY1106964T1 (en) DRUGS CONTAINING N,N'-DIPERAZINE COMPOUNDS AND THEIR USE
ES2170649A1 (en) Use of cdp-choline for the treatment of alcohol withdrawal syndrome
PE20030236A1 (en) DERIVATIVES OF BENZIMIDAZOLE 1-ARIL-2-N, S- OR O-SUBSTITUTES, OBTAINING DRUGS AND PHARMACEUTICAL PREPARATIONS CONTAINING THESE DERIVATIVES
CY1107037T1 (en) USE OF ACETYL L-CARNITINE FOR PREPARATION OF A MEDICINE FOR PREVENTIVE TREATMENT OF POSTOPERATIVE PAIN

Legal Events

Date Code Title Description
B11A Dismissal acc. art.33 of ipl - examination not requested within 36 months of filing
B11Y Definitive dismissal - extension of time limit for request of examination expired [chapter 11.1.1 patent gazette]